Mustafa Prize laureate makes COVID19 vaccine

0 Nov 11 2020 In بین‌المللی

According to German media ‘Deutsche Welle’, due to the outbreak of coronavirus, Mustafa Prize Laureate in 2019 Ugur Sahin has reached significant achievements with regard to producing COVID19 vaccine.

Accordingly, ‘Deutsche Welle’ in a report referred to Sahin achievement the text of which is as ollows

"Lightspeed" is the name of the project that Germany's BioNTech firm launched in mid-January to develop a vaccine against the coronavirus.

It has been moving at approximately that speed since. Vaccines usually takes eight to 10 years to develop, but it might only take the researchers in the German city of Mainz about a year to get theirs approved in the United States.

Sahin was already working in a lab when he was 20. "We had lectures all day until 4 p.m.," Sahin said, "and while my fellow students would go home, I went to the lab to work, usually until 9 or 10 p.m., sometimes until 4 in the morning." When he was done, he would ride home on his bike.


In 1992, Sahin finished medical school and worked as a doctor for internal medicine and hematology and oncology at the University of Cologne for several years before transferring to the Saarland University Medical Center. There, he met Türeci, a medical student and the daughter of a doctor who had come to Germany from Istanbul.

"Rarely have I met anyone as smart as Mr. Sahin, he is always one step ahead of people," Andreas Kuhn, BioNTech's senior vice president of RNA biochemistry and manufacturing, said at the 2019 Mustafa Award ceremony. "If you come up with a new idea, he has already reached that stage and anticipated it."

"Mr. Sahin inspired me from the very beginning," Kuhn said. "I think it is one of his strengths that he can get people excited about the cause." Kuhn said Sahin's scientific arguments are convincing and his enthusiasm for his work is inspiring.

More than 1,300 people from over 60 countries currently work at BioNTech, and more than half of them are women. In October, the German biotech firm debuted on the US's Nasdaq exchange for technology stocks. The company has grown steadily through acquisitions.


Türeci told that she accepts those things she cannot change, but she also tries to "concentrate with determination and courage on things that are within our sphere of influence, which is often greater than you first think." Determination and courage are traits Sahin and Türeci have certainly shown during the pandemic.
Edited On : -/-

No Comments.